TAG:
clinical laboratory testing
Quest Diagnostics Exits 31-Year-Old Lab Venture
By Robert Michel | From the Volume XXIV No. 9 – June 26, 2017 Issue
CEO SUMMARY: News that Quest Diagnostics had exited the long-running CompuNet Clinical Laboratory joint venture in Dayton, Ohio, caught many observers by surprise. The only clues as to possible problems and the motivation of Premier Health, the 51% owner, to buy out Quest’s ownership sh…
Quest Diagnostics Exits 31-Year-Old CompuNet Lab Venture
By Mary Van Doren | From the Volume XXIV No. 9 – June 26, 2017 Issue
This is an excerpt from a 1,362-word article in the June 26, 2017 issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group. CEO SUMMARY: For …
Why Small Labs and Even Hospitals Are at Risk from PAMA Cuts
By Robert Michel | From the Volume XXIII No. 16 – November 28, 2016 Issue
CEO SUMMARY: Clinical lab executives and experts who have studied the final rule for PAMA lab test market price reporting are seriously concerned that the design of this rule may put many of the nation’s smallest, but still essential, clinical labs at great risk of financial distress, i…
Should Labs File Court Challenge To PAMA Price Report Rule?
By Robert Michel | From the Volume XXIII No. 16 – November 28, 2016 Issue
CEO SUMMARY: Just four weeks remain before CMS begins collecting private payer clinical laboratory test price data. Many lab industry executives have charged that Medicare officials are not following the language of the PAMA statute or the intent of Congress. At stake are $5.4 billion in …
10% PAMA Fee Cut Would Lower Medicare Pay to Laboratories by $400 Million
By Joseph Burns | From the Volume XXIII No. 15 – November 7, 2016 Issue
CEO SUMMARY: Just eight weeks remain before certain clinical laboratories must begin submitting private payer lab test price data to the federal Centers for Medicare & Medicaid Services. A new report …
Can Clinical Laboratories Adjust To ‘New’ Healthcare System?
By Robert Michel | From the Volume XXIII No. 14 – October 17, 2016 Issue
CEO SUMMARY: Month by month, there is increased clarity in the path the American healthcare system will follow as hospitals, health systems, and physicians integrate clinical care, manage populations, and practice personalized and precision medicine. While these changes play out, clinical…
October 17, 2016 Intelligence: Late Breaking Lab News
By Robert Michel | From the Volume XXIII No. 14 – October 17, 2016 Issue
Quebec’s provincial health authority is moving forward with what may be one of the largest consolidations of clinical laboratory testing undertaken in North America during the past 30 years. The goal is to bring the lab testing currently done in as many as 500 locations throughout the province int…
Theranos Ends Patient Testing, Sued for Deceiving Investors
By Joseph Burns | From the Volume XXIII No. 14 – October 17, 2016 Issue
IN THE EARLY 1960S, the great bluesman Albert King wrote, “Born Under a Bad Sign,” which contained the unforgettable lyric, “If it wasn’t for bad luck, I wouldn’t have no luck at all.” That lyric almost describes what’s happened to Theranos Inc. since October 2015. Al…
Cepheid, Sequenom Acquisitions Further Consolidate Lab Testing
By Robert Michel | From the Volume XXIII No. 13 – September 26, 2016 Issue
TWO ACQUISITIONS FURTHER consolidated the clinical laboratory testing industry in recent weeks. The acquired companies were Sequenom and Cepheid. Sequenom went first. On July 27, Laboratory Corporation of America announced an agreement to acquire …
Strategy Lowers CalPERS’ Price of Joint Surgeries
By Joseph Burns | From the Volume XXIII No. 12 – September 6, 2016 Issue
CEO SUMMARY: Probably the most-watched reference pricing program in healthcare to date was initiated by CalPERS. It focused on the variability in the prices of knee and hip replacement surgeries. Just as Safeway experienced a drop in clinical lab test prices of 32% in its reference pricin…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized